EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Sam Slutsky reiterated a Buy rating on Eupraxia Pharmaceuticals (EPRX) with an unchanged $16 price target. The recommendation is driven by EP-104GI’s promising Phase 1b/2a RESOLVE data in eosinophilic esophagitis, showing durable symptom relief and histologic response. Despite small cohort limitations, consistent improvements support the drug's potential as a once-yearly therapy. Combined with a two-year cash runway and upcoming Phase 2b catalysts, the risk-reward profile justifies the favorable outlook.
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $16.00.
Sam Slutsky has given his Buy rating due to a combination of factors tied to EP-104GI’s emerging clinical profile and the upcoming Phase 2b data readout. The updated Phase 1b/2a RESOLVE results in eosinophilic esophagitis show durable symptom relief and histologic response, particularly in higher-dose cohorts, reinforcing the potential for EP-104GI as a once-yearly, long-acting therapy that could differentiate meaningfully in a disease with limited treatment options.
While acknowledging the limitations of small, open-label cohorts, Slutsky views the consistency of Straumann Dysphagia Index improvements and sustained clinical remission rates over 36–52 weeks as supportive of the program’s risk-reward profile. Combined with a roughly two-year cash runway, current valuation, and an unchanged $16 price target, he believes the near-term Phase 2b catalyst and long-term commercial opportunity justify a favorable risk-adjusted outlook, underpinning his Buy recommendation on EPRX.